| Literature DB >> 32518254 |
Sonia Chaabane1, Karima Chaabna2, Amit Abraham1, Ravinder Mamtani1, Sohaila Cheema1.
Abstract
To support the global strategy to reduce risk factors for obesity, we synthesized the evidence on physical activity (PA) and sedentary behaviour in the Middle East and North Africa (MENA) region. Our systematic overview included seven systematic reviews reporting 229 primary studies. The meta-analysis included 125 prevalence measures from 20 MENA countries. After 2000, 50.8% of adults (ranging from 13.2% in Sudan to 94.9% in Jordan) and 25.6% of youth (ranging from 8.3% in Egypt to 51.0% in Lebanon) were sufficiently active. Limited data on PA behaviours is available for MENA countries, with the exception of Gulf Cooperation Council countries. The meta-regression identified gender and geographical coverage among youth, and the PA measurement as predictors of PA prevalence for both adults and youth. Our analysis suggests a significant PA prevalence increase among adults over the last two decades. The inconsistency in sedentary behaviour measurement is related to the absence of standardized guidelines for its quantification and interpretation. The global epidemic of insufficient PA is prevalent in MENA. Lower PA participation among youth and specifically females should be addressed by focused lifestyle interventions. The recognition of sedentary behaviour as a public health issue in the region remains unclear. Additional data on PA behaviours is needed from low- and middle-income countries in the region.Entities:
Mesh:
Year: 2020 PMID: 32518254 PMCID: PMC7283267 DOI: 10.1038/s41598-020-66163-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1PRISMA 2009 flowchart of the systematic reviews inclusion.
Quality assessment of the included systematic reviews and the actual overview using AMSTAR checklist.
| Systematic review | 1.Was an ‘a priori’ design provided? | 2.Was there duplicate study selection and data extraction? | 3.Was a comprehensive literature search performed? | 4.Was the status of publication (i.e. grey literature) used as an inclusion criterion? | 5.Was a list of studies (included and excluded) provided? | 6.Were the characteristics of the included studies provided? | 7.Was the scientific quality of the included studies assessed and documented? | 8.Was the scientific quality of the included studies used appropriately in formulating conclusions? | 9.Were the methods used to combine the findings of studies appropriate? | 10.Was the likelihood of publication bias assessed? | 11.Was the conflict of interest included? † |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sisson, 2008[ | No | No | No | No | No | Yes | No | No | N/A | N/A | No |
| Mabry, 2010[ | No | No | Yes | No | No | Yes | Yes | Yes | N/A | N/A | No |
| Ranasinghe, 2013[ | No | Yes | Yes | No | No | Yes | Yes | No | N/A | N/A | No |
| Yammine, 2016[ | No | No | Yes | Yes | No | Yes | No | No | Yes | No | No |
| Mabry, 2016[ | No | Yes | No | No | No | Yes | Yes | Yes | N/A | N/A | No |
| Al-Hazzaa, 2018[ | No | No | Yes | No | No | Yes | No | No | N/A | N/A | No |
| Sharara, 2018[ | Yes | No | Yes | Yes | No | Yes | No | No | N/A | N/A | Yes |
| Current Overview | Yes | Yes | Yes | N/A | Yes | Yes | Yes | Yes | Yes | No | Yes |
Notes: We used the AMSTAR checklist with additional notes made by Michelle Weir, Julia Worswick, and Carolyn Wayne based on conversations with Bev Shea and/or Jeremy Grimshaw in June and October 2008 and July and September 2010. Available on https://amstar.ca/docs/AMSTARguideline.pdf
The absence of a statement regarding any criteria of the quality assessment was considered as not done. The unit of analysis for the systematic reviews is the study. The unit of analysis for the actual overview is the systematic review.
Abbreviations: N/A: Not applicable;
† To get a ‘yes’ for the included SRs, the conflict of interest should be clearly acknowledged for the SR and the included original studies.
To get a ‘yes’ for the actual overview, the conflict of interest should be clearly acknowledged for the actual overview and all included SRs.
Meta-analysis of physical activity prevalence in MENA countries among the adult general population.
| Studied subgroups | Years of data collection | Number of prevalence measures | Total sample size | Prevalence range (%)a | Effect size | Subgroup comparison | Heterogeneity between studies | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Weighted average prevalence (%)b | 95% CI | Q between-subgroups test | Cochrane Q test’s | I² (confidence limits) | 95% Prediction interval (%) | |||||
| All* | 1995–<2017 | 75 | 124,702 | 1.3–95.5 | 47.9 | 40.8–55.0 | N/A | 0.0000 | 99.8% (99.8–99.8%) | 1.8–96.9 |
| Malesc | 1995–<2015 | 29 | 49,343 | 6.1–94.2 | 54.1 | 42.3–65.7 | 0.2286 | 0.0000 | 99.9% (99.8–99.9%) | 2.1–99.7 |
| Femalesc | 1995–<2016 | 32 | 44,167 | 1.3–95.5 | 43.6 | 31.7–55.9 | 0.0000 | 99.8% (99.8–99.9%) | 0.0–98.8 | |
| <2000 | 1995–<2000 | 4 | 19,593 | 1.3–23.1 | 6.2 | 1.7–13.3 | <0.0001 | <0.0001 | 99.6% (99.4–99.7%) | 0.0–56.0 |
| >2000 | 2002–<2017 | 71 | 105,109 | 5.2–95.5 | 50.8 | 45.6–56.0 | 0.0000 | 99.7% (99.6–99.7%) | 11.5–89.6 | |
| All | 1995–2017 | 49 | 72,489 | 1.3–69.2 | 41.7 | 33.7–50 | N/A | 0.0000 | 99.8% (99.8–99.8%) | 0.9–93.1 |
| Malesc | 1995–<2015 | 19 | 34,270 | 6.1–69.2 | 47 | 33.1–61.2 | 0.3836 | 0.0000 | 99.8% (99.8–99.9%) | 0.4–98.3 |
| Femalesc | 1995–<2016 | 22 | 27,256 | 1.3–65.7 | 38.6 | 26.6–51.3 | 0.0000 | 99.8% (99.7–99.8%) | 0.0–93.9 | |
| <2000 | 1995–2000 | 4 | 19,593 | 1.3–23.1 | 6.2 | 1.7–13.3 | <0.0001 | <0.0001 | 99.6% (99.4–99.7%) | 0.0–56.0 |
| >2000 | 2000–2017 | 45 | 52,896 | 13.3–69.2 | 45.7 | 40.5–51.0 | 0.0000 | 99.3% (99.2–99.4%) | 13.8–79.8 | |
| National population | 1995–<2014 | 23 | 44,711 | 1.3–68.0 | 36.8 | 25.9–48.4 | 0.1737 | 0.0000 | 99.8% (99.8–99.8%) | 0.1–90.8 |
| National and non-national populations | <1996–<2016 | 26 | 27,778 | 13.3–69.2 | 46.2 | 38.9–53.6 | 0.0000 | 99.2% (99.1–99.3%) | 11.6–83.1 | |
| All | 1995–2017 | 30 | 52,221 | 1.9–69.2 | 39.9 | 28.8–51.5 | N/A | 0.0000 | 99.8% (99.8–99.9%) | 0.0–95.7 |
| Malesc | 1995–<2015 | 11 | 25,990 | 6.1–69.2 | 42.9 | 22.7–64.4 | 0.8969 | 0.0000 | 99.9% (99.9–99.9%) | 0.0–100.0 |
| Femalesc | 1995–<2016 | 14 | 18,145 | 1.9–65.7 | 41 | 24.5–58.6 | 0.0000 | 99.8% (99.7–99.8%) | 0.0–98.8 | |
| <2000 | 1995–2000 | 2 | 17,395 | 1.9–6.1 | 3.7 | 0.7–9.0 | <0.0001 | <0.0001 | 99.5% (99.2–99.7%) | N/A |
| >2000 | 2003–2017 | 28 | 34,826 | 13.3–69.2 | 43.3 | 36.0–50.8 | 0.0000 | 99.4% (99.4–99.5%) | 8.7–82.2 | |
| National population | 1995–<2014 | 10 | 30,296 | 1.9–65.7 | 29.5 | 16.5–44.4 | 0.0712 | 0.0000 | 99.8% (99.8–99.9%) | 0.0–85.2 |
| National and non-national populations | 2005–2017 | 20 | 21,925 | 13.3–69.2 | 45.2 | 36.5–54.1 | 0.0000 | 99.3% (99.1–99.4%) | 9.3–84.4 | |
| All | 2000–2003 | 5 | 2,459 | 43.2–67.4 | 57.8 | 49.1–66.3 | N/A | < 0.0001 | 94.4% (89.6–96.9%) | 25.2–87.0 |
| Malesc | 2002–2003 | 2 | 1,646 | 62.1–66.5 | 64.3 | 59.9–68.6 | <0.0001 | 0.0621 | 71.3% (0.0–93.5%) | N/A |
| Femalesc | 2002–2003 | 2 | 638 | 43.2–49.4 | 46.3 | 40.3–52.4 | 0.1165 | 59.4% (0.0%–90.5%) | N/A | |
| <2000 | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2000–2003 | 5 | 2,459 | 43.2–67.4 | 57.8 | 49.1–66.3 | <0.0001 | 94.4% (89.6–96.9%) | 25.2–87.0 | |
| National population | 2003 | 2 | 1,180 | 49.4–66.5 | 58.2 | 41.2–74.2 | 0.9558 | <0.0001 | 96.5% (90.5–98.7%) | N/A |
| National and non-national populations | 2000–2003 | 3 | 1,279 | 43.2–67.4 | 57.6 | 44.0–70.6 | <0.0001 | 94.9% (88.4–97.7%) | 0.0–100.0 | |
| All | 2008 | 2 | 3,137 | 59.5–68.0 | 63.8 | 55.3–71.9 | N/A | < 0.0001 | 95.9% (88.4–98.6%) | N/A |
| Males | 2008 | 1 | 1,459 | N/A | 68.0 | 65.5–70.4 | N/A | N/A | N/A | N/A |
| Females | 2008 | 1 | 1,678 | N/A | 59.5 | 57.1–61.8 | N/A | N/A | N/A | |
| <2000 | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2008 | 2 | 3,137 | 59.5–68.0 | 63.8 | 55.3–71.9 | <0.0001 | 95.9% (88.4–98.6%) | N/A | |
| National population | 2008 | 2 | 3,137 | 59.5–68.0 | 63.8 | 55.3–71.9 | N/A | < 0.0001 | 95.9% (88.4–98.6%) | N/A |
| National and non-national populations | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| All | 1995–1996 | 2 | 2,198 | 1.3–23.1 | 9.3 | 0.0–40.2 | N/A | < 0.0001 | 99.7% (99.5–99.8%) | N/A |
| Males | 1995–1996 | 1 | 1,297 | N/A | 23.1 | 20.9–25.5 | N/A | N/A | N/A | |
| Females | 1995–1996 | 1 | 901 | N/A | 1.3 | 0.7–2.3 | N/A | N/A | N/A | |
| <2000 | 1995–1996 | 2 | 2,198 | 1.3–23.1 | 9.3 | 0.0–40.2 | N/A | < 0.0001 | 99.7% (99.5–99.8%) | N/A |
| >2000 | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| National population | 1995–1996 | 2 | 2,198 | 1.3–23.1 | 9.3 | 0.0–40.2 | N/A | < 0.0001 | 99.7% (99.5–99.8%) | N/A |
| National and non-national populations | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| All | 2003–<2015 | 5 | 4,382 | 39.5–62.6 | 49.3 | 41.5–57.1 | N/A | < 0.0001 | 96.3% (93.7–97.8%) | 20.6–78.2 |
| Malesc | 2003 | 2 | 1537 | 49.1–62.6 | 56.0 | 42.7–68.9 | 0.0782 | <0.0001 | 96.0% (88.9–98.6%) | N/A |
| Femalesc | 2003–2012 | 2 | 2,113 | 39.5–45.8 | 42.8 | 36.7–49 | 0.0058 | 86.8% (48.2% 96.7%) | N/A | |
| <2000 | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2003–<2015 | 5 | 4,382 | 39.5–62.6 | 49.3 | 41.5–57.1 | <0.0001 | 96.3% (93.7–97.8%) | 20.6–78.2 | |
| National population | 2003–2012 | 4 | 3,650 | 39.5–62.6 | 49.3 | 39.4–59.3 | 0.9982 | <0.0001 | 97.2% (95.1–98.4%) | 8.3–90.9 |
| National and non-national populations | <2015 | 1 | 732 | N/A | 49.3 | 45.7–52.9 | N/A | N/A | N/A | |
| All* | 2006–2014 | 5 | 8,092 | 27.2–48.6 | 36.5 | 28.7–44.7 | N/A | < 0.0001 | 98.2% (97.3–98.9%) | 9.8–68.8 |
| Malesc | 2006–2014 | 2 | 2341 | 42.1–48.6 | 45.4 | 39.1–51.9 | <0.0001 | 0.0020 | 89.6% (61.2%–97.2%) | N/A |
| Femalesc | 2006–2014 | 2 | 3,781 | 27.2–28.4 | 27.7 | 26.2–29.1 | 0.4233 | 0.0% | N/A | |
| <2000 | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2006–2014 | 5 | 8,092 | 27.2–48.6 | 36.5 | 28.7–44.7 | <0.0001 | 98.2% (97.3–98.9%) | 9.8–68.8 | |
| National population | 2006–<2013 | 3 | 4,250 | 28.4–42.1 | 35.7 | 28.5–43.2 | 0.8676 | <0.0001 | 96.0% (91.4–98.1%) | 0.0–100.0 |
| National and non-national populations | 2014 | 2 | 3,842 | 27.2–48.6 | 37.6 | 18.3–59.3 | N/A | N/A | N/A | |
| All | 2002–<2010 | 4 | 6,144 | 30.2–87.2 | 61.0 | 41.4–78.9 | N/A | < 0.0001 | 99.5% (99.3–99.6%) | 0.0–100.0 |
| Males | 2002–<2010 | 2 | 3,114 | 47.9–87.2 | 69.5 | 27.7–97.7 | 0.5557 | <0.0001 | 99.5% (99.2–99.7%) | N/A |
| Females | 2002–<2010 | 2 | 3,030 | 30.2–72.7 | 51.7 | 13.2–89.1 | <0.0001 | 99.4% (99.0–99.7%) | N/A | |
| <2000 | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2002–<2010 | 4 | 6,144 | 30.2–87.2 | 61.0 | 41.4–78.9 | <0.0001 | 99.5% (99.3–99.6%) | 0.0–100.0 | |
| All | 2002–2009 | 3 | 6,212 | 55.6–89.0 | 76.8 | 55.9–92.5 | N/A | < 0.0001 | 99.7% (99.6–99.8%) | 0.0–100.0 |
| Malesc | 2002–2003 | 1 | 2,149 | N/A | 89.0 | 87.6–90.3 | N/A | N/A | N/A | N/A |
| Femalesc | 2002–2003 | 1 | 2,183 | N/A | 81.8 | 80.1–83.4 | N/A | N/A | N/A | |
| <2000 | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2002–2009 | 3 | 6,212 | 55.6–89.0 | 76.8 | 55.9–92.5 | <0.0001 | 99.7% (99.6–99.8%) | 0.0–100.0 | |
| All | 2000–2014 | 4 | 5,461 | 24.0–59.8 | 41.5 | 27.0–56.7 | N/A | < 0.0001 | 99.2% (98.9–99.5%) | 0.0–98.6 |
| Malesc | 2008–2009 | 1 | 893 | N/A | 47.8 | 44.5–51.2 | N/A | N/A | N/A | N/A |
| Femalesc | 2008–2009 | 1 | 1,089 | N/A | 59.8 | 56.8–62.7 | N/A | N/A | N/A | N/A |
| <2000 | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2000–2014 | 4 | 5,461 | 24.0–59.8 | 41.5 | 27.0–56.7 | N/A | < 0.0001 | 99.2% (98.9–99.5%) | 0.0–98.6 |
| All | 2008 | 3 | 5,233 | 54.6–83.5 | 69.3 | 50.6–85.2 | N/A | < 0.0001 | 99.5% (99.2–99.6%) | 0.0–100.0 |
| Malesc | 2008 | 1 | 1,359 | N/A | 67.6 | 65.1–70.1 | N/A | N/A | N/A | N/A |
| Femalesc | 2008 | 1 | 1,261 | 54.6 | 51.8–57.4 | N/A | N/A | N/A | ||
| <2000 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2008 | 3 | 5,233 | 54.6–83.5 | 69.3 | 50.6–85.2 | <0.0001 | 99.5% (99.2–99.6%) | 0.0–100.0 | |
| All | 2012 | 1 | 5,300 | N/A | 67.9 | 66.6–69.2 | N/A | N/A | N/A | N/A |
| Males | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Females | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| <2000 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2012 | 1 | 5,300 | N/A | 67.9 | 66.6–69.2 | N/A | N/A | N/A | |
| All | 2010–2011 | 1 | 6,957 | N/A | 53.5 | 52.3–54.7 | N/A | N/A | N/A | N/A |
| Males | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Females | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| <2000 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2010–2011 | 1 | 6,957 | N/A | 53.5 | 52.3–54.7 | N/A | N/A | N/A | N/A |
| All | 2005–2006 | 2 | 1,573 | 5.2–24.2 | 13.2 | 0.8–36.7 | N/A | N/A | N/A | N/A |
| Males | 2005–2006 | 1 | 652 | N/A | 24.2 | 21.0–27.7 | N/A | N/A | N/A | N/A |
| Females | 2005–2006 | 1 | 921 | N/A | 5.2 | 3.9–6.9 | N/A | N/A | N/A | N/A |
| <2000 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2005–2006 | 2 | 1,573 | 5.2–24.2 | 13.2 | 0.8–36.7 | N/A | N/A | N/A | N/A |
| All | 2003 | 2 | 4,101 | 54.2–67.5 | 61.0 | 47.7–73.5 | N/A | N/A | N/A | N/A |
| Males | 2003 | 1 | 1,599 | N/A | 67.5 | 65.2–69.8 | N/A | N/A | N/A | N/A |
| Females | 2003 | 1 | 2,502 | N/A | 54.2 | 52.3–56.2 | N/A | N/A | N/A | |
| <2000 | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2003 | 2 | 4,101 | 54.2–67.5 | 61.0 | 47.7–73.5 | N/A | N/A | N/A | N/A |
| All | 2009 | 2 | 3,590 | N/A | 56.2 | 40.8–71.1 | N/A | N/A | N/A | N/A |
| Males | 2009 | 1 | 1,800 | N/A | 64.0 | 61.7–66.2 | N/A | N/A | N/A | N/A |
| Females | 2009 | 1 | 1,790 | N/A | 48.3 | 46.0–50.7 | N/A | N/A | N/A | |
| <2000 | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2009 | 2 | 3,590 | N/A | 56.2 | 40.8–71.1 | N/A | N/A | N/A | N/A |
| All | 2007 | 2 | 3,654 | N/A | 94.9 | 93.5–96.1 | N/A | N/A | N/A | N/A |
| Males | 2007 | 1 | 1,939 | N/A | 94.2 | 93.1–95.2 | N/A | N/A | N/A | N/A |
| Females | 2007 | 1 | 1,715 | N/A | 95.5 | 94.4–96.4 | N/A | N/A | N/A | N/A |
| <2000 | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2007 | 2 | 3,654 | N/A | 94.9 | 93.5–96.1 | N/A | N/A | N/A | N/A |
| All | 2015 | 2 | 3,988 | N/A | 52.6 | 28.4–76.2 | N/A | N/A | N/A | N/A |
| Males | 2015 | 1 | 1,568 | N/A | 65.1 | 62.7–67.5 | N/A | N/A | N/A | N/A |
| Females | 2015 | 1 | 2,420 | N/A | 40.0 | 38.0–42.0 | N/A | N/A | N/A | N/A |
| <2000 | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2015 | 2 | 3,988 | N/A | 52.5 | 28.4–76.2 | N/A | N/A | N/A | N/A |
Notes: Mean effect size reported as weighted average prevalence measure with their corresponding 95% confidence interval (CI); the p-value of the Cochran’s Q statistic is used to inform about the statistical significance of the heterogeneity in PA prevalence estimates within the group; the p-value of the Cochran’s Q between-subgroups statistic is used to inform about the statistical significance of the heterogeneity in PA prevalence estimates between the results of subgroups if applicable; the I2 is used to assess the magnitude of between-study variation that is due to differences in PA prevalence estimates across studies rather than chance; the prediction interval is used to estimate the 95% interval in which the true PA prevalence in a new PA prevalence study will lie. No meta-analyses according to the time of data collection were then performed. p-value <0.05 was considered statistically significant. Meta-analyses according to the type of population (nationals and non-national populations) were only relevant in the GCC countries as per the type of setting of the GCC population. Years of data collection were considered as prior to the publication year in studies where this information was missing. The prevalence measures were then classified accordantly for the meta-analyses. <2000: this analysis includes all studies where the data was collected before 2000. > 2000: this analysis includes all studies where the data was collected before 2000.
Symbols:
*Include converted data from physical inactivity to physical activity not overlapping with other included data.
aStratified prevalence measures were used to conduct the meta-analyses.
bWeighted average prevalence measures were obtained using random-effect model.
cExcluded the studies with a mixed male and female population.
Meta-analysis of physical activity prevalence in MENA countries among the youth general population.
| Studied subgroups | Years of data collection | Number of prevalence measures | Total sample | Prevalence range (%) a | Effect size | Subgroup comparison | Heterogeneity between studies | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Weighted average prevalence (%) b | 95% CI | Q between-subgroups test | Cochrane Q test’s | I² (confidence limits) | 95% Prediction interval (%) | |||||
| All* | <1993-<2018 | 50 | 78,915 | 4.0–79.9 | 25.4 | 21.8–29.1 | N/A | 0.0000 | 99.3% (99.2–99.3%) | 4.9–54.7 |
| Malesc | <1993-<2015 | 19 | 20,811 | 14.0–79.9 | 37.1 | 28.8–45.8 | <0.0001 | 0.0000 | 99.4% (99.3–99.5%) | 5.2–77.7 |
| Femalesc | 2004-<2018 | 16 | 18,606 | 4.0–52.2 | 16.5 | 12.2–21.2 | <0.0001 | 98.5% (98.2–98.8%) | 2.1–40.4 | |
| <2000 | <1993- <2000 | 1 | 212 | N/A | 15.1 | 10.6–20.6 | 0.0014 | N/A | N/A | N/A |
| >2000 | 2002-<2018 | 49 | 78,703 | 4.0–79.9 | 25.6 | 22.0–29.4 | 0.0000 | 99.3% (99.2–99.4%) | 5.0–55.0 | |
| GCC | ||||||||||
| All* | <1993-<2018 | 25 | 34,323 | 4.0–79.9 | 33.3 | 26.7–40.3 | N/A | 0.0000 | 99.4% (99.4–99.5%) | 5.1–71.0 |
| Malesc | <1993-<2015 | 12 | 12,522 | 15.1–79.9 | 48.9 | 36.7–61.2 | 0.0002 | <0.0000 | 99.4% (99.3–99.5%) | 7.1–91.7 |
| Femalesc | 2004-<2018 | 9 | 10,637 | 4.0–52.2 | 21.7 | 15.1–29.1 | <0.0001 | 98.5% (98.0–98.9%) | 2.6–52.1 | |
| <2000 | <1993 | 1 | 212 | N/A | 15.1 | 10.6–20.6 | <0.0001 | N/A | N/A | N/A |
| >2000 | 2004-<2018 | 24 | 34,111 | 4.0–79.9 | 34.1 | 27.3–41.3 | 0.0000 | 99.5% (99.4–99.5%) | 5.4–72.0 | |
| National population | 2005–2010 | 5 | 4,110 | 21.9–70.4 | 47.7 | 29.3–66.6 | 0.0771 | <0.0001 | 99.3% (99.0–99.5%) | 0.0–99.8 |
| National and non-national populations | <1993- <2018 | 20 | 30,213 | 4.0–79.9 | 29.9 | 23.4–36.8 | 0.0000 | 99.4% (99.3–99.5%) | 4.7–64.9 | |
| All | <1993-<2018 | 9 | 6,884 | 4.0–79.9 | 34.1 | 19.7–50.1 | N/A | < 0.0001 | 99.4% (99.3–99.5%) | 0.0–89.7 |
| Malesc | <1993-<2015 | 6 | 4,360 | 15.1–79.9 | 47.2 | 33.0–61.7 | 0.0007 | <0.0001 | 98.9% (98.4–99.2%) | 4.6–92.8 |
| Femalesc | 2009-<2018 | 3 | 2,524 | 4.0–21.9 | 12.2 | 3.1–26.1 | <0.0001 | 98.6% (97.5–99. 2%) | 0.0–100.0 | |
| <2000 | <1993 | 1 | 212 | N/A | 15.1 | 10.6–20.6 | 0.0083 | N/A | N/A | N/A |
| >2000 | 2005-<2018 | 8 | 6,672 | 4.0–79.9 | 36.7 | 21.1–53.9 | <0.0001 | 99.5% (99.4–99.6%) | 0.0–92.8 | |
| National population | 2005–2010 | 3 | 3,204 | 21.9–55.5 | 42.9 | 19.2–68.4 | 0.4506 | <0.0001 | 99.5% (99.2–99.7%) | 0.0–100.0 |
| National and non-national populations | <1993- <2018 | 6 | 3,680 | 4.0–79.9 | 29.8 | 11.0–53.1 | <0.0001 | 99.5% (99.4–99.6%) | 0.0–99.1 | |
| All | 2004–2010 | 7 | 14,447 | 18.0–74.5 | 35.0 | 24.7–46.1 | N/A | < 0.0001 | 99.4% (99.2–99.5%) | 4.6–75.2 |
| Malesc | 2004–2010 | 3 | 6,206 | 21.4–74.5 | 44.2 | 17.1–73.3 | 0.3889 | <0.0001 | 99.7% (99.6–99.8%) | 0.0–100.0 |
| Femalesc | 2004–2010 | 3 | 6,203 | 18.0–52.2 | 29.0 | 12.9–48.4 | <0.0001 | 99.2% (98.7–99.5%) | 0.0–100.0 | |
| <2000 | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2004–2010 | 7 | 14,447 | 18.0–74.5 | 35.0 | 24.7–46.1 | <0.0001 | 99.4% (99.2–99.5%) | 4.6–75.2 | |
| National population | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| National and non-national populations | 2004–2010 | 7 | 14,447 | 18.0–74.5 | 35.0 | 24.7–46.1 | <0.0001 | 99.4% (99.2–99.5%) | 4.6–75.2 | |
| All | 2005–2015 | 5 | 6,428 | 11.7–66.7 | 28.8 | 14.6–45.6 | N/A | < 0.0001 | 99.4% (99.2–99.5%) | 0.0–90.6 |
| Malesc | 2005–2010 | 2 | 1,493 | 34.0–66.7 | 50.3 | 19.8–80.6 | 0.0532 | <0.0001 | 99.2% (98.4–99.6%) | N/A |
| Femalesc | 2005–2010 | 2 | 1,467 | 16.0–23.1 | 19.3 | 12.8–26.7 | 0.0016 | 90.0% (63.2–97.3%) | N/A | |
| <2000 | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2005–2015 | 5 | 6,428 | 11.7–66.7 | 28.8 | 14.6–45.6 | <0.0001 | 99.4% (99.2–99.5%) | 0.0–90.6 | |
| National population | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| National and non-national populations | 2005–2015 | 5 | 6,428 | 11.7–66.7 | 28.8 | 14.6–45.6 | <0.0001 | 99.4% (99.2–99.5%) | 0.0–90.6 | |
| All | 2009–2015 | 3 | 4,543 | 17.1–70.4 | 41.4 | 11.7–75.2 | N/A | < 0.0001 | 99.7% (99.5–99.8%) | 0.0–100.0 |
| Malesc | 2009 | 1 | 463 | N/A | 70.4 | 66.0–74.5 | N/A | N/A | N/A | N/A |
| Femalesc | 2009 | 2 | 443 | N/A | 39.3 | 34.7–44.0 | N/A | N/A | N/A | |
| <2000 | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2009–2015 | 3 | 4,543 | 17.1–70.4 | 41.4 | 11.7–75.2 | <0.0001 | 99.7% (99.5–99.8%) | 0.0–100.0 | |
| National population | 2009 | 2 | 906 | 39.3–70.4 | 55.1 | 25.1–83.2 | 0.0099 | <0.0001 | 98.9% (97.8–99.5%) | N/A |
| National and non-national populations | 2015 | 1 | 3637 | N/A | 17.1 | 15.9–18.3 | N/A | N/A | N/A | |
| All | 2009–2011 | 2 | 3154 | 34.6–67.4 | 51.0 | 20.4–81.3 | N/A | < 0.0001 | 99.6% (99.4–99.8%) | N/A |
| Malesc | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Femalesc | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| <2000 | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2009–2011 | 2 | 3154 | 34.6–67.4 | 51.0 | 20.4–81.3 | <0.0001 | 99.6% (99.4–99.8%) | N/A | |
| All | 2002–2010 | 4 | 13,784 | 18.3–24.2 | 21 | 18.4–23.7 | N/A | < 0.0001 | 89.7% (76.5–95.5%) | 10.4–34.1 |
| Malesc | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Femalesc | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| <2000 | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2002–2010 | 4 | 13,784 | 18.3–24.2 | 21 | 18.4–23.7 | <0.0001 | 89.7% (76.5–95.5%) | 10.4–34.1 | |
| All | 2012 | 1 | 2,038 | N/A | 20.0 | 18.3–21.8 | N/A | N/A | N/A | N/A |
| Malesc | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Femalesc | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| <2000 | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2012 | 1 | 2,038 | N/A | 20.0 | 18.3–21.8 | N/A | N/A | N/A | |
| All | 2011 | 1 | 2,021 | N/A | 15.0 | 13.5–16.5 | N/A | N/A | N/A | N/A |
| Malesc | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Femalesc | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| <2000 | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2011 | 1 | 2,021 | N/A | 15.0 | 13.5–16.5 | N/A | N/A | N/A | |
| National population | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| National and non-national populations | 2011 | 1 | 2,021 | N/A | 15.0 | 13.5–16.5 | N/A | N/A | N/A | |
| All | 2006–2010 | 4 | 4,659 | 13.0–20.8 | 16.6 | 12.6–21 | N/A | < 0.0001 | 93.3% (86.2–96.8%) | 2.2–40.5 |
| Malesc | 2006–2010 | 2 | 2,546 | 20.0–20.8 | 20.5 | 19.0–22.1 | <0.0001 | 0.6257 | 0.0% | N/A |
| Femalesc | 2006–2010 | 2 | 2,113 | 13.0–13.3 | 13.2 | 11.7–14.6 | 0.8581 | 0.0% | N/A | |
| <2000 | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2006–2010 | 4 | 4,659 | 13.0–20.8 | 16.6 | 12.6–21 | <0.0001 | 93.3% (86.2–96.8%) | 2.2–40.5 | |
| All | 2007 | 2 | 2,242 | 11.6–21.5 | 16.2 | 7.8–27.0 | N/A | < 0.0001 | 97.5% (93.8–99.0%) | N/A |
| Malesc | 2007 | 1 | 1,123 | N/A | 21.5 | 19.1–24.0 | N/A | N/A | N/A | N/A |
| Femalesc | 2007 | 1 | 1,119 | N/A | 11.6 | 9.8–13.6 | N/A | N/A | N/A | |
| <2000 | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2007 | 2 | 2,242 | 11.6–21.5 | 16.2 | 7.8–27.0 | <0.0001 | 97.5% (93.8–99.0%) | N/A | |
| All | 2004–2007 | 4 | 3,916 | 11.0–20.0 | 15.9 | 12.1–20.1 | N/A | < 0.0001 | 91.8% (82.2–96.2%) | 2.2–38.6 |
| Malesc | 2004–2007 | 2 | 1,938 | 18.2–20.0 | 19.0 | 17.3–20.8 | 0.0078 | 0.3143 | 1.2% | N/A |
| Femalesc | 2004–2007 | 2 | 1,978 | 11.0–14.9 | 12.9 | 9.3–17.0 | 0.0098 | 85% (39.1–96.3%) | N/A | |
| <2000 | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2004–2007 | 4 | 3,916 | 11.0–20.0 | 15.9 | 12.1–20.1 | <0.0001 | 91.8% (82.2–96.2%) | 2.2–38.6 | |
| All | 2012 | 1 | 2,211 | N/A | 11 | 9.7–12.4 | N/A | N/A | N/A | N/A |
| Malesc | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Femalesc | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| <2000 | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2012 | 1 | 2,211 | N/A | 11 | 9.7–12.3 | N/A | N/A | N/A | |
| All | 2006 | 2 | 3,664 | 4.0–14.0 | 8.3 | 1.3–20.5 | N/A | < 0.0001 | 99.2% (98.4–99.6%) | N/A |
| Malesc | 2006 | 1 | 1,975 | N/A | 14.0 | 12.5–15.6 | 0.0000 | N/A | N/A | N/A |
| Femalesc | 2006 | 1 | 1,689 | N/A | 4.0 | 3.1–5.1 | N/A | N/A | N/A | |
| <2000 | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2006 | 2 | 3,664 | 4.0–14.0 | 8.3 | 1.3–20.5 | <0.0001 | 99.2% (98.4–99.6%) | N/A | |
| All | 2007 | 2 | 1,777 | 9.2–18.8 | 13.6 | 5.6–24.4 | N/A | < 0.0001 | 97.1% (92.3–98.9%) | N/A |
| Malesc | 2c007 | 1 | 707 | N/A | 18.8 | 16.0–21.9 | <0.0000 | N/A | N/A | N/A |
| Females | 2007 | 1 | 1,070 | N/A | 9.2 | 7.5–11.0 | N/A | N/A | N/A | |
| <2000 | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2007 | 2 | 1,777 | 9.2–18.8 | 13.6 | 5.6–24.4 | <0.0001 | 97.1% (92.3–98.9%) | N/A | |
| All | 2010 | 1 | 3,102 | N/A | 15.1 | 13.8–16.4 | N/A | N/A | N/A | N/A |
| Malesc | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Femalesc | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| <2000 | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2010 | 1 | 3,102 | N/A | 15.1 | 13.8–16.4 | N/A | N/A | N/A | |
| All | 2008 | 1 | 2,870 | N/A | 18.5 | 17.1–20.0 | N/A | N/A | N/A | N/A |
| Malesc | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Femalesc | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| <2000 | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2008 | 1 | 28,70 | N/A | 18.5 | 17.1–20.0 | N/A | N/A | N/A | |
| All | 2008 | 1 | 1,175 | N/A | 15.2 | 13.2–17.4 | N/A | N/A | N/A | N/A |
| Malesc | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Femalesc | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| <2000 | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| >2000 | 2008 | 1 | 1,175 | N/A | 15.2 | 13.2–17.4 | N/A | N/A | N/A | |
Notes: Mean effect size reported as weighted average prevalence measure with their corresponding 95% confidence interval (CI); the p-value of the Cochran’s Q statistic is used to inform about the statistical significance of the heterogeneity in PA prevalence estimates within the group; the p-value of the Cochran’s Q between-subgroups statistic is used to inform about the statistical significance of the heterogeneity in PA prevalence estimates between the results of subgroups if applicable; the I2 is used to assess the magnitude of between-study variation that is due to differences in PA prevalence estimates across studies rather than chance; the prediction interval is used to estimate the 95% interval in which the true PA prevalence in a new PA prevalence study will lie. p-value <0.05 was considered statistically significant. <2000: this analysis includes all studies where the data was collected before 2000. > 2000: this analysis includes all studies where the data was collected before 2000.
Meta-analyses according to the type of population (nationals and non-national populations) were only relevant in the GCC countries as per the type of setting of the GCC population. Years of data collection were considered as prior to the publication year in studies where this information was missing. The prevalence measures were then classified accordantly for the meta-analyses. All data among youth was collected after 2000.
Symbols:
* Include converted data from physical inactivity to physical activity not overlapping with other included data.
**include data from an included primary study not reported by the SR.
*** Data on moderate and vigorous physical activity levels were merged in the studies of Wasfi, 2008[36] and Mehairi, 2013[34], respectively, to ovoid partial overlapping of denominators data from the same study.
aStratified prevalence measures were used to conduct the meta-analyses.
bWeighted average prevalence measures were obtained using random-effect model.
cExcluded the studies with a mixed male and female population.
Figure 2Map of the physical activity prevalence measures, using data collected after 2000: (A) In the adult MENA population, (B) in the youth MENA population, and (C) in the national GCC adult and youth populations. All PA data were collected after 2000. MENA countries with no PA prevalence measures among adults include Djibouti, Yemen, Bahrain, and Syria. MENA countries with no PA prevalence measures among youth include Algeria, Bahrain and Pakistan. Heterogeneity (I2) between the PA prevalence measures varied between 99.6–99.7% in adults and 99.2–99.4% in youth in MENA countries. Among GCC nationals, heterogeneity (I2) between the PA prevalence measures varied between 99.8–99.8% in adults and 99.0–99.5% in youth. N/A is used to indicate the non-availability of disaggregated prevalence data according to gender in (A,B) and age (adult/youth) in (C).
Univariate meta-regression models for physical activity prevalence in MENA adult and youth general population.
| Meta-regression variables | Variables categories | Number of prevalence measures | Total sample size | Effect size | Univariable analyses | Proportion of explained true variance | |||
|---|---|---|---|---|---|---|---|---|---|
| Weighted average prevalence (%) | 95% CI | OR | 95% CI | p-value† | R2 (%) | ||||
| Gender | Male | 29 | 49,343 | 54.1 | 42.3–65.7 | 1.11 | 0.94–1.32 | 0.2286 | 2.72 |
| Female | 32 | 44,167 | 43.6 | 31.7–55.9 | Ref. | Ref. | |||
| Data collection time | > 2000 | 71 | 105,109 | 50.8 | 45.6–56.0 | 52.89 | |||
| <2000 | 4 | 19,593 | 6.2 | 1.7–13.3 | Ref. | Ref. | |||
| PA measurement tools | IPAQ | 19 | 19,317 | 57.4 | 47.2–67.1 | 41.42 | |||
| “How physically active are you” questionnaire | 2 | 322 | 21.4 | 17.3–26.2 | 0.92 | 0.64–1.32 | 0.6408 | ||
| GPAQ | 37 | 74,049 | 51.1 | 42.8–59.3 | |||||
| Nurses’ Health Study II | 1 | 175 | 67.4 | 60.1–74.0 | 1.48 | 0.91–2.42 | 1.5641 | ||
| ATLS | 3 | 1,177 | 55.8 | 48.1–63.1 | 1.31 | 0.97–1.78 | 0.0782 | ||
| Non-validated | 13 | 29,662 | 23.9 | 11.9–42.1 | Ref. | Ref. | Ref. | ||
| Geographical coverage | Country level | 42 | 98,662 | 50.4 | 39.8–60.9 | 1.08 | 0.93–1.25 | 0.3034 | 0.00 |
| Local level | 33 | 26,040 | 42.7 | 36.1–49.7 | Ref. | Ref. | |||
| Gender | Male | 19 | 20,811 | 37.1 | 28.8–45.8 | 19.37 | |||
| Female | 16 | 18,606 | 16.5 | 12.2–21.2 | Ref. | Ref. | |||
| Data collection time | > 2000 | 49 | 78,703 | 25.6 | 22.0–29.4 | 1.14 | 0.84–1.54 | 0.4050 | 0.00 |
| <2000 | 1 | 212 | 15.1 | 10.6–20.3 | Ref. | Ref. | |||
| PA measurement tools | Objective measurement | 2 | 508 | 32.6 | 3.9–72.3 | 0.91 | 0.75–1.11 | 0.3569 | 35.35 |
| ATLS | 8 | 5,886 | 38.9 | 22.7–56.4 | 0.97 | 0.85–1.10 | 0.6381 | ||
| HBSC | 2 | 9199 | 20.1 | 19.1–21.0 | |||||
| PACE + | 30 | 57,763 | 17.1 | 14.9–19.5 | |||||
| IPAQ | 2 | 1,018 | 63.7 | 41.0–83.6 | |||||
| Non-validated | 6 | 4,541 | 28.0 | 13.9–48.3 | Ref. | Ref. | Ref. | ||
| Geographical coverage | Country level | 34 | 68,422 | 20.3 | 17.3–23.3 | 21.70 | |||
| Local level | 16 | 10,493 | 37.4 | 26.7–48.8 | Ref. | Ref. | |||
Notes: Significant results are highlighted in bold. Association between the meta-regression variable and the prevalence of PA is reported as an odds ratio (OR) with its corresponding 95% confidence interval. Mean effect size reported as weighted average prevalence measure with their corresponding 95% confidence interval (CI). Weighted average prevalence measures were obtained using random-effect model. Proportion of total between-study variance explained by the model (R[2]) is used to assess the magnitude of the covariates relationship with effect size[30]. All data among youth was collected after 2000. No meta-analyses according to the time of data collection were then performed. The category “Country level” includes all prevalence measures based on a national sample of individuals representative of the entire country where the study was conducted (e.g. all cities of the country). To be included in this category, a study should clearly mention that the study was conducted at the national level. Any study based on a sample from a restricted part of the country (one or few cities, specific university, specific school, etc.) is considered in the “Local level” category.
†p-value <0.05 was considered statistically significant.
Abbreviations: PA: Physical activity; MENA: Middle East and North Africa; IPAQ: International physical activity questionnaire; GPAQ: Global physical activity questionnaire; ATLS: Arab Teens Lifestyle Study questionnaire; HBSC: Health Behaviour in School-aged Children Survey, PACE+: Adolescent physical activity measure questionnaire.
Barriers to physical activity and correlates of physical inactivity in MENA.
| In high income countries* | In low- and middle-income income countries** |
|---|---|
| • Lower levels of urbanization and built environment (eg: Lack of parks, greenery, squares, playgrounds, sports venues)[ | • Rapid urbanization (eg: Access to motorization; Highdensity traffic; Low air quality; Pollution)[ |
| • The physical environment factors (eg: Proximity to | • The physical environment factors (eg: Proximity to |
| destinations; Neighbourhood aesthetics; Access toopen space)[ | The physical environment factors (eg: Proximity to destinations; Neighborhood aesthetics; Access to open space)[ |
| • Psychological and social factors (eg: Unperceived | • Psychological and social factors (eg: Unperceived |
| benefits of PA and healthy status; Low self-efficacy; | benefits of PA and healthy status; Low self-efficacy; |
| Absence of social support from friends and peers; | Absence of social support from friends and peers; |
| Lack of exercise partner)[ | Lack of exercise partner)[ |
| • Hot arid climate[ | • Hot arid climate[ |
| • The employment of domestic helpers[ | • Cultural expectations (traditional role of women in taking care of household work and supporting extended family members)[ |
| • Conservative social norms particularly relevant for women[ | • Sociodemographic factors (eg: Age; Sex; Education level)[ |
| • Work-related factors (eg: Working long hours; Working in private sector)[ | • Lifestyle factors (eg: Lack of time; Poor sleeping habits; High screen time) [ |
| • Sociodemographic factors (eg: Age; Sex; Education level)[ | |
| • Lifestyle factors (eg: Lack of time; Poor sleeping habits; High screen time)[ |
*Including GCC countries.
**Including MENA countries other than GCC.
Public health implications and recommendations.
| • Public health efforts to increase PA and decrease sedentary time require standardized PA surveillance among all countries in the region. These measures are necessary to understand locally informed interventional strategies and to identify target populations affected by physical inactivity. This requires building and strengthening country capacity with a systems approach to scale up efforts aimed at increasing PA. |
| • Health-care providers can adopt a comprehensive curriculum that potentially closes the gap in medical schools, residency programs, graduate education, and nursing curricula on topics related to PA, and exercise prescription and lifestyle health[ |
| • Current data suggests that MENA youth population is insufficiently active. Physical environment interventions like parks, playgrounds, sports venues, proximity to destinations, and neighbourhood aesthetics can be beneficial. Additionally, psychosocial factors such as self-efficacy and social support from peers should also be considered while planning interventions. |
| • Identifying and considering PA-relevant domains (e.g. transportation, leisure-time PA) and barriers specific to the MENA populations are essential for adapting national actions and policies to tackle obesity and other non-communicable diseases. |
| • Considering the increasing urbanization in the region[ |
| • Clear guidelines for sedentary behaviour measurement and interpretation in order to characterize patterns of sedentary behaviour in the MENA countries are required. |
Evidence gap and future research.
| There is a need to: |
| • Clarify standardized methods of measuring PA, inactivity and sedentary behaviour for future studies. |
| • Conduct large and up-to-date country-level studies using standardized tools and definitions to quantify PA participation[ |
| • Generate data on PA-related outcomes in MENA countries other than the GCC countries. |
| • Explore differences in PA participation between nationals and non-nationals in the GCC countries. |
| • Further understand the personal, social and environmental barriers to PA, particularly in relation to the different domains of PA (leisure time, occupational, transports, and households PA) specific to the region[ |
| • Identify target population groups (girls, youth, obese) for focused interventions[ |
| • Follow PA trends over time[ |